A randomized controlled trial of the cost-utility of second-generation antipsychotics in people with psychosis and eligible for clozapine.
OBJECTIVE: To assess whether clozapine is likely to be more cost-effective than other second-generation antipsychotics (SGAs) in people with schizophrenia. METHODS: An integrated clinical and economic multicenter, rater-blind, randomized controlled trial (RCT) compared clozapine to the class of oth...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2008
|
| _version_ | 1797075807179374592 |
|---|---|
| author | Davies, L Barnes, T Jones, P Lewis, S Gaughran, F Hayhurst, K Markwick, A Lloyd, H |
| author_facet | Davies, L Barnes, T Jones, P Lewis, S Gaughran, F Hayhurst, K Markwick, A Lloyd, H |
| author_sort | Davies, L |
| collection | OXFORD |
| description | OBJECTIVE: To assess whether clozapine is likely to be more cost-effective than other second-generation antipsychotics (SGAs) in people with schizophrenia. METHODS: An integrated clinical and economic multicenter, rater-blind, randomized controlled trial (RCT) compared clozapine to the class of other SGAs, using the perspectives of the National Health Service, social support services, and patients. The practice setting was secondary and primary care in the United Kingdom; patients were followed for 1 year. Incremental cost-effectiveness ratios (ICERs), net benefit statistics, and cost acceptability curves were estimated. RESULTS: The ICER for clozapine was 33,240 pound per quality-adjusted life-year (QALY) (range 23,000-70,000 pound for the sensitivity analyses). The proportion of simulations when clozapine was more cost-effective than other SGAs reached 50% if decision-makers are prepared to pay 30,000 pound to 35,000 pound per QALY. This is at the top of the range of acceptable willingness-to-pay values per QALY implied by decisions taken by the National Institute for Health and Clinical Excellence (NICE). CONCLUSIONS: This study adds to a limited body of evidence comparing clozapine to other SGAs and is the first economic and clinical RCT to compare clozapine to the class of other SGAs using the lower cost of generic clozapine and a pragmatic trial design. Policy decisions by the NICE suggest that additional reasons would be needed to accept clozapine as effective and efficient if it had a high probability of having ICERs more than 35,000 pound per QALY. The results and limitations of the analysis suggest that there is still a need for further economic evaluation of clozapine. |
| first_indexed | 2024-03-06T23:55:23Z |
| format | Journal article |
| id | oxford-uuid:7408c1fb-5e95-4226-b724-a29ea5146f7e |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:55:23Z |
| publishDate | 2008 |
| record_format | dspace |
| spelling | oxford-uuid:7408c1fb-5e95-4226-b724-a29ea5146f7e2022-03-26T20:00:13ZA randomized controlled trial of the cost-utility of second-generation antipsychotics in people with psychosis and eligible for clozapine.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:7408c1fb-5e95-4226-b724-a29ea5146f7eEnglishSymplectic Elements at Oxford2008Davies, LBarnes, TJones, PLewis, SGaughran, FHayhurst, KMarkwick, ALloyd, H OBJECTIVE: To assess whether clozapine is likely to be more cost-effective than other second-generation antipsychotics (SGAs) in people with schizophrenia. METHODS: An integrated clinical and economic multicenter, rater-blind, randomized controlled trial (RCT) compared clozapine to the class of other SGAs, using the perspectives of the National Health Service, social support services, and patients. The practice setting was secondary and primary care in the United Kingdom; patients were followed for 1 year. Incremental cost-effectiveness ratios (ICERs), net benefit statistics, and cost acceptability curves were estimated. RESULTS: The ICER for clozapine was 33,240 pound per quality-adjusted life-year (QALY) (range 23,000-70,000 pound for the sensitivity analyses). The proportion of simulations when clozapine was more cost-effective than other SGAs reached 50% if decision-makers are prepared to pay 30,000 pound to 35,000 pound per QALY. This is at the top of the range of acceptable willingness-to-pay values per QALY implied by decisions taken by the National Institute for Health and Clinical Excellence (NICE). CONCLUSIONS: This study adds to a limited body of evidence comparing clozapine to other SGAs and is the first economic and clinical RCT to compare clozapine to the class of other SGAs using the lower cost of generic clozapine and a pragmatic trial design. Policy decisions by the NICE suggest that additional reasons would be needed to accept clozapine as effective and efficient if it had a high probability of having ICERs more than 35,000 pound per QALY. The results and limitations of the analysis suggest that there is still a need for further economic evaluation of clozapine. |
| spellingShingle | Davies, L Barnes, T Jones, P Lewis, S Gaughran, F Hayhurst, K Markwick, A Lloyd, H A randomized controlled trial of the cost-utility of second-generation antipsychotics in people with psychosis and eligible for clozapine. |
| title | A randomized controlled trial of the cost-utility of second-generation antipsychotics in people with psychosis and eligible for clozapine. |
| title_full | A randomized controlled trial of the cost-utility of second-generation antipsychotics in people with psychosis and eligible for clozapine. |
| title_fullStr | A randomized controlled trial of the cost-utility of second-generation antipsychotics in people with psychosis and eligible for clozapine. |
| title_full_unstemmed | A randomized controlled trial of the cost-utility of second-generation antipsychotics in people with psychosis and eligible for clozapine. |
| title_short | A randomized controlled trial of the cost-utility of second-generation antipsychotics in people with psychosis and eligible for clozapine. |
| title_sort | randomized controlled trial of the cost utility of second generation antipsychotics in people with psychosis and eligible for clozapine |
| work_keys_str_mv | AT daviesl arandomizedcontrolledtrialofthecostutilityofsecondgenerationantipsychoticsinpeoplewithpsychosisandeligibleforclozapine AT barnest arandomizedcontrolledtrialofthecostutilityofsecondgenerationantipsychoticsinpeoplewithpsychosisandeligibleforclozapine AT jonesp arandomizedcontrolledtrialofthecostutilityofsecondgenerationantipsychoticsinpeoplewithpsychosisandeligibleforclozapine AT lewiss arandomizedcontrolledtrialofthecostutilityofsecondgenerationantipsychoticsinpeoplewithpsychosisandeligibleforclozapine AT gaughranf arandomizedcontrolledtrialofthecostutilityofsecondgenerationantipsychoticsinpeoplewithpsychosisandeligibleforclozapine AT hayhurstk arandomizedcontrolledtrialofthecostutilityofsecondgenerationantipsychoticsinpeoplewithpsychosisandeligibleforclozapine AT markwicka arandomizedcontrolledtrialofthecostutilityofsecondgenerationantipsychoticsinpeoplewithpsychosisandeligibleforclozapine AT lloydh arandomizedcontrolledtrialofthecostutilityofsecondgenerationantipsychoticsinpeoplewithpsychosisandeligibleforclozapine AT daviesl randomizedcontrolledtrialofthecostutilityofsecondgenerationantipsychoticsinpeoplewithpsychosisandeligibleforclozapine AT barnest randomizedcontrolledtrialofthecostutilityofsecondgenerationantipsychoticsinpeoplewithpsychosisandeligibleforclozapine AT jonesp randomizedcontrolledtrialofthecostutilityofsecondgenerationantipsychoticsinpeoplewithpsychosisandeligibleforclozapine AT lewiss randomizedcontrolledtrialofthecostutilityofsecondgenerationantipsychoticsinpeoplewithpsychosisandeligibleforclozapine AT gaughranf randomizedcontrolledtrialofthecostutilityofsecondgenerationantipsychoticsinpeoplewithpsychosisandeligibleforclozapine AT hayhurstk randomizedcontrolledtrialofthecostutilityofsecondgenerationantipsychoticsinpeoplewithpsychosisandeligibleforclozapine AT markwicka randomizedcontrolledtrialofthecostutilityofsecondgenerationantipsychoticsinpeoplewithpsychosisandeligibleforclozapine AT lloydh randomizedcontrolledtrialofthecostutilityofsecondgenerationantipsychoticsinpeoplewithpsychosisandeligibleforclozapine |